• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Val769_Asp770insAlaSerVal (c.2308_2309insCCAGCGTGG) (c.2300_2308dup) (M766_A767insASV) (p.Ala767_Val769dupAlaSerVal) (A767_V769dupASV); ClinVar=VCV000177678; Zygosity=Heterozygous (DOI=10.1158/1535-7163.TARG-19-LB-B05).
  

PubMed=29748209; DOI=10.1158/1535-7163.MCT-17-1206
Hasako S., Terasaka M., Abe N., Uno T., Ohsawa H., Hashimoto A., Fujita R., Tanaka K., Okayama T., Wadhwa R., Miyadera K., Aoyagi Y., Yonekura K., Matsuo K.
TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations.
Mol. Cancer Ther. 17:1648-1658(2018)

DOI=10.1158/1535-7163.TARG-19-LB-B05
Kelter G., Peille A.-L., Fehr J., Klett H., Maier A., Posch M., Metz T.M.
Characterization of a panel of 79 PDX-derived cell lines with a focus on the EGFR exon 20 insertion mutation-driven NSCLC model LXFE 2478.
Mol. Cancer Ther. 18 Suppl. 12:LBB05-LBB05(2019)

PubMed=31467113; DOI=10.1158/1541-7786.MCR-19-0419; PMCID=PMC6872223
Udagawa H., Hasako S., Ohashi A., Fujioka R., Hakozaki Y., Shibuya M., Abe N., Komori T., Haruma T., Terasaka M., Fujita R., Hashimoto A., Funabashi K., Yasuda H., Miyadera K., Goto K., Costa D.B., Kobayashi S.S.
TAS6417/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations.
Mol. Cancer Res. 17:2233-2243(2019)